The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive transcriptomic analysis of immune checkpoint markers in a pancancer cohort: Implications for response and resistance.
 
Hirotaka Miyashita
No Relationships to Disclose
 
Nicholas J. Bevins
No Relationships to Disclose
 
Kartheeswaran Thangathurai
No Relationships to Disclose
 
Suzanna Lee
No Relationships to Disclose
 
Sarabjot Pabla
Employment - Omniseq
Patents, Royalties, Other Intellectual Property - Patent pending at Omniseq (Inst)
 
Mary Nesline
Stock and Other Ownership Interests - OmniSeq
 
Sean Glenn
Stock and Other Ownership Interests - OmniSeq
 
Jeffrey M. Conroy
Stock and Other Ownership Interests - OmniSeq
 
Paul DePietro
Stock and Other Ownership Interests - OmniSeq
 
Eitan Rubin
No Relationships to Disclose
 
Jason K. Sicklick
Stock and Other Ownership Interests - Personalis
Consulting or Advisory Role - Deciphera
Speakers' Bureau - Deciphera; Foundation Medicine; Merck; MJH Life Sciences; QED Therapeutics; Roche
Research Funding - Amgen; Foundation Medicine
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Pfizer/EMD Serono
Speakers' Bureau - Bayer
Research Funding - ACT Genomics; Konica Minolta; OmniSeq; Sysmex
 
Razelle Kurzrock
Leadership - CureMatch; CureMetrix
Stock and Other Ownership Interests - CureMatch; CureMetrix; IDbyDNA
Honoraria - AACR; Advanced Therapeutics; Bicara Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; Foundation Medicine; LEK; Merck; Meyer Consulting; NeoGenomics Laboratories; NeoMed; Pfizer; Roche; Turning Point Therapeutics; Wiley
Consulting or Advisory Role - Actuate Therapeutics; AstraZeneca; Bicara Therapeutics; Biological Dynamics; Daiichi Sankyo; Eisai; EOM Pharmaceuticals; Gaido; Iylon; Loxo; Merck; NeoMed; Pfizer; Prosperdtx; Roche; Soluventis; TD2/Volastra; Turning Point Therapeutics; XBiotech
Speakers' Bureau - Roche
Research Funding - Biological Dynamics (Inst); Boehringer Ingelheim (Inst); Debiopharm Group (Inst); Foundation Medicine (Inst); Genentech (Inst); Grifols (Inst); Guardant Health (Inst); Incyte (Inst); Konica Minolta (Inst); MedImmune (Inst); Merck Serono (Inst); OmniSeq (Inst); Pfizer (Inst); Sequenom (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - AACR; Advanced Therapeutics; Biocom; Chugai Pharma USA; EUSA Pharma; LEK; NeoGenomics Laboratories; NeoMed; Roche; Wiley